Crovalimab
Phase 3Active 1 views this week 0 watching⚡ Active
Interest: 44/100
44
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Atypical Hemolytic Uremic Syndrome
Conditions
Atypical Hemolytic Uremic Syndrome
Trial Timeline
Oct 22, 2021 → Aug 20, 2029
NCT ID
NCT04861259About Crovalimab
Crovalimab is a phase 3 stage product being developed by Chugai Pharmaceutical for Atypical Hemolytic Uremic Syndrome. The current trial status is active. This product is registered under clinical trial identifier NCT04861259. Target conditions include Atypical Hemolytic Uremic Syndrome.
What happened to similar drugs?
1 of 7 similar drugs in Atypical Hemolytic Uremic Syndrome were approved
Approved (1) Terminated (0) Active (6)
Hype Score Breakdown
Clinical
17
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04958265 | Phase 3 | Active |
| NCT04861259 | Phase 3 | Active |
Competing Products
18 competing products in Atypical Hemolytic Uremic Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Crovalimab | Chugai Pharmaceutical | Phase 3 | 44 |
| Duloxetine | Eli Lilly | Approved | 43 |
| Teriparatide 20 mcg | Eli Lilly | Phase 3 | 40 |
| Baricitinib | Eli Lilly | Pre-clinical | 26 |
| Ravulizumab | AstraZeneca | Pre-clinical | 33 |
| Eculizumab | AstraZeneca | Phase 3 | 40 |
| Iptacopan | Novartis | Phase 3 | 44 |
| Iptcaopan 200 mg | Novartis | Phase 3 | 47 |
| Iptacopan | Novartis | Phase 3 | 47 |
| Ropeginterferon Alfa-2B | PharmaEssentia | Phase 2 | 42 |
| CCX168 | Amgen | Phase 2 | 27 |
| Tazemetostat + Nivolumab + Ipilimumab | Bristol Myers Squibb | Phase 1/2 | 39 |
| Cemdisiran | Alnylam Pharmaceuticals | Phase 2 | 24 |
| cemdisiran + Placebos | Alnylam Pharmaceuticals | Phase 2 | 24 |
| Axatilimab + Azacitidine | Incyte | Phase 1/2 | 36 |
| Gemcitabine + Paxalisib | Pacific Biosciences | Phase 2 | 32 |
| Apatinib Mesylate | Brain Biotech | Pre-clinical | 23 |
| azurin-derived cell-penetrating peptide p28 | Brain Biotech | Phase 1 | 19 |